Atosiban

Generic Name: Atosiban

Brand Names: Tractocile, Atosiban SUN

Drug Type: Small Molecule

Chemical Formula: C_₄₃H_₆₇N_₁₁O_₁₂S_₂

CAS Number: 90779-69-4

Unique Ingredient Identifier: 081D12SI0Z

Background: Atosiban is an inhibitor of the hormones oxytocin and vasopressin. It is used intravenously to halt premature labor. Although initial studies suggested it could be used as a nasal spray and hence would not require hospital admission, it is not used in that form. Atobisan was developed by the Swedish company Ferring Pharmaceuticals. It was first reported in t...

Indication: Atosiban is indicated for use in delaying imminent pre-term birth in pregnant adult women with:

Associated Conditions: Premature Births

Associated Therapies: -

Clinical Trials

Perioperative Use of Atosiban for Ultrasound-indicated Cerclage to Reduce Spontaneous Preterm Birth(sPTB)

Not Applicable

Completed

Conditions: Premature Birth
Cervical Cerclage

Interventions: Drug: Atosiban
Drug: Normal saline

First Posted Date: 2024-08-05

Last Posted Date: 2024-08-06

Lead Sponsor: Children's Hospital of Chongqing Medical University

Target Recruit Count: 334

Registration Number: NCT06537778

Locations: 🇨🇳
Women and Children's Hospital of Chongqing Medical University, Chongqing, Chognqing, China
🇨🇳
The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China

Atosiban Versus Placebo in the Treatment of Late Threatened Pre-term Birth

Phase 4

Completed

Conditions: Preterm Birth

Interventions: Drug: Atosiban

First Posted Date: 2023-01-23

Last Posted Date: 2024-07-25

Lead Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Target Recruit Count: 760

Registration Number: NCT05693688

Locations: 🇳🇱
Amsterdam University Medical Centres, location AMC, Amsterdam, Noord-Holland, Netherlands

The Effect of Selective Oxytocin Receptor Inhibitors on Endometriosis-related Pain

Phase 2

Conditions: Endometriosis

Interventions: Drug: Atosiban

First Posted Date: 2022-05-19

Last Posted Date: 2022-05-19

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 10

Registration Number: NCT05382143

Locations: 🇳🇱
Radboud University Medical Center, Nijmegen, Netherlands

In Utero Repair of Myelomeningocele: Atosiban Versus Terbutaline

Completed

Conditions: Myelomeningocele
Terbutaline Adverse Reaction
Pregnancy; Malformation Central Nervous System

Interventions: Drug: Atosiban
Drug: Terbutaline

First Posted Date: 2020-07-13

Last Posted Date: 2022-06-06

Lead Sponsor: University of Sao Paulo General Hospital

Target Recruit Count: 25

Registration Number: NCT04468568

Locations: 🇧🇷
Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

Effect of Oxytocin Antagonists on Implantation Success Rates of Frozen-thawed Embryo Transfer

Not Applicable

Conditions: Infertility, Female

Interventions: Drug: Atosiban

First Posted Date: 2019-04-05

Last Posted Date: 2020-12-16

Lead Sponsor: Bezmialem Vakif University

Target Recruit Count: 250

Registration Number: NCT03904745

Locations: 🇹🇷
Yeditepe University, Istanbul, Turkey
🇹🇷
Bezmialem University, Istanbul, Turkey

Oxidative Stress in Women Treated With Atosiban for Impending Preterm Birth

Not Applicable

Completed

Conditions: Premature Birth

Interventions: Drug: Atosiban

First Posted Date: 2018-06-26

Last Posted Date: 2019-06-14

Lead Sponsor: Polish Mother Memorial Hospital Research Institute

Target Recruit Count: 64

Registration Number: NCT03570294

Locations: 🇵🇱
Department of Obstetrics, Perinatology and Gynecology, Polish Mother's Memorial Hospital-Research Institute, Łódź, Poland

PoC Study of OBE022 in Threatened Preterm Labour

Phase 2

Conditions: Preterm Labor

Interventions: Drug: OBE022
Drug: Placebos
Drug: Atosiban

First Posted Date: 2017-12-11

Last Posted Date: 2021-06-07

Lead Sponsor: ObsEva SA

Target Recruit Count: 115

Registration Number: NCT03369262

Locations: 🇮🇱
Rabin Medical Center, Fetal-Maternal Medicine, Helen Schneider's Hospital for Women, Petah tikva, Israel
🇮🇱
Rambam Medical Center, Maternal Fetal Unit, Haifa, Israel
🇨🇿
Gynekologicko-porodnická klinika Fakultní nemocnice Brno, Brno, Czechia

and more 15 locations

A Randomized Double Blind Comparison of Atosiban in Patients With RIF Undergoing IVF Treatment

Phase 1

Conditions: Repeated Implantation Failure

Interventions: Drug: 0.9% saline
Drug: atosiban

First Posted Date: 2016-09-08

Last Posted Date: 2016-09-08

Lead Sponsor: Shanghai First Maternity and Infant Hospital

Target Recruit Count: 200

Registration Number: NCT02893722

Tocolytic Therapy for Preterm Labor in Multiple Gestation

Phase 3

Conditions: Labor Preterm Multiple

Interventions: Drug: Atosiban
Drug: Nifedipine

First Posted Date: 2016-04-01

Last Posted Date: 2016-04-01

Lead Sponsor: Tel-Aviv Sourasky Medical Center

Target Recruit Count: 140

Registration Number: NCT02725736

Follow up Study to Assess Long Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies

Phase 3

Completed

Conditions: Obstetric Labour, Premature

Interventions: Drug: Placebo
Drug: Atosiban
Drug: Retosiban

First Posted Date: 2014-11-17

Last Posted Date: 2020-07-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 98

Registration Number: NCT02292784

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy